PRKCB and glioblastoma: Enzastaurin is a novel inhibitor of PKCβ that interferes with angiogenesis and cell proliferation and has shown good tolerability and activity in clinical studies in glioblastoma and lymphoma (Fine et al, 2005; Carducci et al, 2006).